Technology & Products
From a pinhole to a panorama
Proteins are functional drivers of biology and thus key indicators of status in any living organism. To truly understand biology, we must empower researchers with the tools necessary to discover, annotate, and understand the rich universe of the proteome.
For decades, a critical limiting factor has been the inability to access the proteome in an unbiased, deep manner rapidly and at the scale necessary to survey and understand its diversity.
To create a more transformative view of the proteome, we had to create a new technology; one that provides a new lens on the proteome, enabling researchers to see the breadth, depth and dynamic nature of proteome diversity across populations and time. This is done across orders of magnitude of protein abundance; and is applicable to longitudinal population studies in a rapid and robust manner. While technologies exist today that can provide one or more of these attributes, Seer is expected to be the first to combine them all into a single, efficient workflow.
We aim to empower researchers to see more of the proteome and understand more of its diversity
Develop better markers for early disease detection
Improve the timeline and probability of success for therapeutic development
Our approach starts with proprietary engineered nanoparticles developed to maximize proteomic insights – simply and robustly.
Seer’s technology delivers the unique combination of attributes necessary for a transformative approach to proteomics:
Unbiased coverage:
See what’s there– not just what you are searching for or what you can capture
Deep access:
Survey and represent the entire dynamic range of the proteome – even in complex samples such as plasma and serum
Rapid workflow:
Rely on an optimized, robust workflow to complete your projects – fast and with minimal hands on time
Scalable technology:
Scale both assay design and study size – including large sample longitudinal studies
See more of the proteome
The unique properties of Seer’s engineered nanoparticles enable you to explore the proteome in new ways
Broad affinity range:
Reproducible and selective binding without prior knowledge, using engineered nanoparticles that allow unbiased interrogation of proteoforms
Quantitative compression of the dynamic range renders low abundant proteins visible to detectors
Tunable physiochemical properties:
Nearly infinite combination of distinct nanoparticle designs to survey the full richness of proteoform diversity
Removes complexity of experiments
Power proteomic discovery with the Proteograph™ product suite
Designed for unbiased, deep, and rapid proteomics experiments that scale without sacrifice
The Proteograph™ suite of products includes optimized reagents and consumables, automation, and software. Its protocols integrate seamlessly with nearly all existing mass spectrometers. Our product suite is designed to enable you to complete a proteomics study with an unprecedented combination of speed, efficiency, and data output.
The Proteograph workflow is optimized for multiple samples in a single run and includes quality controls to ensure robust measurements. With it, you’ll accurately survey thousands of proteins with precision—and without sacrificing nuance—in hours. The Proteograph solution delivers the quantitation, accuracy, precision, and reproducibility you need to tackle proteome studies of varying sizes with confidence.
The Proteograph™ product suite :
Consumables
Simple, elegant preparation
Put Seer’s proprietary nanoparticles to work with an easy-to-use assay solution.
Instruments
A single, unified workflow
Go from sample to seeing more quickly, using Seer’s liquid handling automation solution.
Mass Spectrometry*
Seamless lab integration
Integrate with the LC-MS/MS your lab already uses.
* User Supplied
Data Analysis
A clearer view of the proteome
A scalable analysis suite to QC, analyze and integrate data with a scalable analysis suite for reliable insights.
First name Last name
Title goes here
Philip Ma is the Chief Business Officer for Seer. Previously, he was Vice-President for Digital Health Technologies and Data Sciences at Biogen, a group that he established in 2015 to discover insights and create value for Biogen and its patients. Prior to joining Biogen, Philip was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice for the Firm. Active in community affairs, Philip also serves on the Board of Committee of 100, a group of Chinese-American business and community leaders focused on U.S. China relations and the Asian-American experience. Before McKinsey, Philip was a macromolecular crystallographer in the lab of Dr. Carl O. Pabo at Massachusetts Institute of Technology, where he received his Ph.D. in Biology. Philip also has degrees in Biochemistry (A.B. from Harvard College) and in Economics (MPhil from Oxford University, where he was a Rhodes Scholar).